| Literature DB >> 26395859 |
Hannah V McCue1, Xi Chen1, Jeff W Barclay1, Alan Morgan1, Robert D Burgoyne1.
Abstract
Cysteine string protein (CSP) is a chaperone of the Dnaj/Hsp40 family of proteins and is essential for synaptic maintenance. Mutations in the human gene encoding CSP, DNAJC5, cause adult neuronal ceroid lipofucinosis (ANCL) which is characterised by progressive dementia, movement disorders, seizures and premature death. CSP null models in mice, flies and worms have been shown to also exhibit similar neurodegenerative phenotypes. Here we have explored the mechanisms underlying ANCL disease progression using Caenorhaditis elegans mutant strains of dnj-14, the worm orthologue of DNAJC5. Transcriptional profiling of these mutants compared to control strains revealed a broad down-regulation of ubiquitin proteasome system (UPS)-related genes, in particular, components of multimeric RING E3 ubiquitin ligases including F-Box, SKR and BTB proteins. These data were supported by the observation that dnj-14 mutant worm strains expressing a GFP-tagged ubiquitin fusion degradation substrate exhibited decreased ubiquitylated protein degradation. The results indicate that disruption of an essential synaptic chaperone leads to changes in expression levels of UPS-related proteins which has a knock-on effect on overall protein degradation in C. elegans. The specific over-representation of E3 ubiquitin ligase components revealed in our study, suggests that proteins and complexes upstream of the proteasome itself may be beneficial therapeutic targets.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26395859 PMCID: PMC4585785 DOI: 10.1038/srep14392
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Venn Diagrams and a heatmap representing differentially regulated genes.
(A) Venn diagrams illustrating the number of up and down-regulated genes for both the 5% and 1% FDR datasets in dnj-14 mutants compared to either N2 or CZ1200 and the number of common genes between the two control strains. (B) Microarray data heatmap illustrating the log2 fold change of DEGs (FDR < 0.01) common to both, tm3223 and ok237, dnj-14 mutant strains compared to N2 and CZ1200 control strains. Each row represents one of 213 genes, and each column represents the comparison of each mutant strain to each control strain. The column on the left clusters the samples based on similarity in fold change among the 4 samples. Green color represents a lower log2 fold change while red illustrates a higher log2 fold change. The scale on the right matches colours to log2 fold change values.
David Functional Annotation for the down-regulated genes in 5% and 1% FDR datasets.
| Annotation Term | 5% FDR | 1% FDR | |||
|---|---|---|---|---|---|
| P-Value | Fold Enrichment | P-Value | Fold Enrichment | ||
| Biological Process | GO:0006355~regulation of transcription, DNA-dependent | 1.33E-04 | 2.80 | 0.003985128 | 2.64 |
| GO:0051252~regulation of RNA metabolic process | 1.40E-04 | 2.78 | 0.004123515 | 2.63 | |
| GO:0006511~ubiquitin-dependent protein catabolic process | 1.49E-04 | 8.51 | 2.45E-04 | 10.32 | |
| GO:0045449~regulation of transcription | 4.50E-04 | 2.43 | 0.016440945 | 2.17 | |
| GO:0044265~cellular macromolecule catabolic process | 0.0014285 | 4.67 | 0.006409969 | 4.96 | |
| GO:0019941~modification-dependent protein catabolic process | 0.002640061 | 4.94 | 0.002855343 | 6.00 | |
| GO:0043632~modification-dependent macromolecule catabolic process | 0.002640061 | 4.94 | 0.002855343 | 6.00 | |
| GO:0042464~dosage compensation, by hypoactivation of X chromosome | 0.003032918 | 34.84 | — | — | |
| GO:0051603~proteolysis involved in cellular protein catabolic process | 0.003323413 | 4.72 | 0.003485241 | 5.72 | |
| GO:0044257~cellular protein catabolic process | 0.003430888 | 4.69 | 0.003582778 | 5.69 | |
| GO:0007549~dosage compensation | 0.003768035 | 31.35 | — | — | |
| GO:0009057~macromolecule catabolic process | 0.003815176 | 3.93 | 0.013037275 | 4.17 | |
| GO:0030163~protein catabolic process | 0.005373442 | 4.28 | 0.005292688 | 5.19 | |
| GO:0010171~body morphogenesis | 0.007835542 | 2.33 | — | — | |
| GO:0007530~sex determination | 0.049688021 | 8.25 | — | — | |
| GO:0006508~proteolysis | 0.054970961 | 2.01 | 0.020161301 | 2.56 | |
| Molecular Function | GO:0003700~transcription factor activity | 6.23E-05 | 3.08 | 1.19E-03 | 3.04 |
| GO:0030528~transcription regulator activity | 7.45E-05 | 2.77 | 6.70E-03 | 2.44 | |
| GO:0003677~DNA binding | 7.43E-04 | 2.23 | 7.13E-03 | 2.18 | |
| KEGG Pathway | cel04120:Ubiquitin mediated proteolysis | 5.46E-05 | 8.32 | 2.42E-05 | 11.89 |
| Protein Domain (Interpro) | IPR012885:F-Box associated type 2 | 3.15E-42 | 21.09 | 1.50E-41 | 24.24 |
| IPR001810:Cyclin-like F-Box | 7.41E-30 | 9.37 | 3.79E-28 | 10.30 | |
| IPR011333:BTB/POZ fold | 2.87E-10 | 8.91 | 1.88E-09 | 9.66 | |
| IPR001699:Transcription factor, T-box | 2.08E-09 | 33.51 | 3.46E-05 | 25.97 | |
| IPR016897:E3 ubiquitin ligase, SCF complex, Skp subunit | 3.13E-08 | 34.20 | 4.47E-07 | 36.35 | |
| IPR018186:Transcription factor, T-box, conserved site | 6.41E-08 | 30.78 | 7.48E-04 | 21.81 | |
| IPR016072:SKP1 component, dimerisation | 6.41E-08 | 30.78 | 7.98E-07 | 32.72 | |
| IPR001232:SKP1 component | 1.62E-07 | 26.77 | 1.69E-06 | 28.45 | |
| IPR016073:SKP1 component, POZ | 2.79E-07 | 24.63 | 2.64E-06 | 26.18 | |
| IPR000571:Zinc finger, CCCH-type | 4.26E-05 | 15.08 | 1.50E-05 | 18.70 | |
| IPR000210:BTB/POZ-like | 2.50E-04 | 5.42 | 3.71E-04 | 5.98 | |
| IPR013069:BTB/POZ | 0.005488655 | 5.28 | 2.17E-03 | 6.54 | |
DAVID Functional Annotation Clustering gene list for down-regulated genes in the 1% FDR dataset.
| Cluster | Ensembl ID | Gene Name | Human Orthologue | Average Fold Change |
|---|---|---|---|---|
| F-BOX proteins (Enrichment Score = 29.35) | F58E1.5 | — | 2.58 | |
| M116.4 | — | 2.16 | ||
| K05F6.7 | — | 2.08 | ||
| F53C3.2 | — | 2.00 | ||
| Y51H7BR.2 | — | 1.97 | ||
| R17.1 | — | 1.97 | ||
| F08D12.10 | — | 1.97 | ||
| Y43B11AL.1 | — | 1.91 | ||
| T26E3.5 | — | 1.87 | ||
| ZC204.7 | — | 1.87 | ||
| R08C7.9 | — | 1.81 | ||
| F45C12.5 | — | 1.80 | ||
| F58E1.14 | — | 1.80 | ||
| W04A8.5 | — | 1.78 | ||
| F58E1.8 | — | 1.78 | ||
| M01D1.8 | — | 1.78 | ||
| T08E11.6 | — | 1.74 | ||
| F55C9.13 | — | 1.73 | ||
| ZC204.9 | — | 1.70 | ||
| F56G4.3 | — | 1.68 | ||
| F12E12.10 | — | 1.68 | ||
| M151.5 | — | 1.66 | ||
| W04A8.3 | — | 1.65 | ||
| C52E2.1 | — | 1.65 | ||
| C39B5.2 | — | 1.64 | ||
| Y46G5A.8 | — | 1.63 | ||
| H24O09.2 | — | 1.60 | ||
| F36H5.8 | — | 1.60 | ||
| T26E3.8 | — | 1.59 | ||
| F08D12.9 | — | 1.53 | ||
| F55C9.8 | — | 1.51 | ||
| F45D11.13 | — | 1.50 | ||
| F49B2.2 | — | 1.48 | ||
| T16A1.8 | — | 1.48 | ||
| Y113G7B.8 | — | 1.44 | ||
| T17A3.4 | — | 1.43 | ||
| C08F1.3 | — | 1.41 | ||
| C36C9.3 | — | 1.40 | ||
| BTB/POZ domain proteins (Enrichment Score = 4.22) | M01D1.3 | — | 2.07 | |
| R52.1 | Isoform 2 of Kelch-like protein 28 | 2.04 | ||
| K02E7.9 | — | 1.87 | ||
| Y105C5B.13 | Isoform 1 of S-phase kinase-associated protein 1 | 1.87 | ||
| C52D10.8 | Uncharactersised protein | 1.85 | ||
| B0281.5 | potassium channel tetramerization domain containing 10 | 1.85 | ||
| F54D10.1 | Uncharactersised protein | 1.75 | ||
| C52D10.7 | Isoform 1 of S-phase kinase-associated protein 1 | 1.74 | ||
| Y47D7A.8 | Uncharactersised protein | 1.69 | ||
| F45C12.6 | — | 1.64 | ||
| C52D10.9 | Isoform 1 of S-phase kinase-associated protein 1 | 1.61 | ||
| C40A11.2 | potassium channel tetramerization domain containing 10 | 1.54 | ||
| ZC204.3 | — | 1.50 | ||
| F45C12.7 | — | 1.50 | ||
| Transcription Factors (Enrichment Score = 2.55) | Y47D3A.12 | T-box transcription factor TBX21 | 2.26 | |
| ZK662.4 | Isoform 1 of Uncharacterized protein C6orf132 | 2.23 | ||
| C24H11.3 | TBX6 | 2.00 | ||
| Y46E12A.4 | Eomesodermin homolog | 1.88 | ||
| F17A2.5 | pre-B-cell leukemia homeobox 1 | 1.68 | ||
| F40H6.4 | T-box transcription factor TBX21 | 1.67 | ||
| C29F7.4 | Uncharactersised protein | 1.67 | ||
| C32F10.6 | highly similar to Retinoic acid receptor gamma-2 | 1.63 | ||
| C50F4.6 | Histone H2B type 1-L | 1.57 | ||
| F19F10.5 | Isoform 2 of ETS domain-containing protein Elk-4 | 1.56 | ||
| C30A5.2 | Isoform 1 of DNA repair protein RAD51 homolog 4 | 1.41 | ||
| F19B10.9 | Isoform 1 of T-box transcription factor TBX22 | 1.37 | ||
| ZC376.4 | NOBOX oogenesis homeobox | 1.29 | ||
| ZC204.2 | double homeobox protein 4-like protein 4 | 1.27 |
The enrichment score for each cluster is given in the first column and the average fold decrease for the two dnj-14 mutants compared to the two control strains is given in the last column.
Regulatory motif analysis.
| Motif | ID | Exp Occ (%) | 5% FDR | 1% FDR | Enrichment Score | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Occ (%) | P-Value | Score | Occ (%) | P-Value | Score | F-Box | BTB | |||
| atcgata | atcgata|tatcgat | 8 | 29 | 1.70E-26 | 21.84 | 33 | 1.40E-21 | 16.95 | 14.24 | 2.98 |
| atcgat | atcgat|atcgat | 15 | 39 | 3.10E-23 | 19.19 | 44 | 6.50E-21 | 16.87 | 19.4 | 4.53 |
| tatcga | tatcga|tcgata | 20 | 40 | 3.80E-17 | 13.11 | 43 | 1.20E-17 | 13.62 | 22.47 | 3.39 |
| acgctg | acgctg|cagcgt | 6 | 20 | 1.10E-14 | 10.65 | 23 | 4.90E-15 | 11 | 3.47 | — |
The four most significantly overrepresented motifs in both the 5% and 1% FDR datasets (up- and down-regulated genes combined) are shown in this table. Lists of genes containing each of these motifs were analysed by DAVID functional clustering analysis and an enrichment score for F-Box and BTB proteins was generated. Exp Occ = expected occurrence, Occ = actual occurrence. The score was generated by RSAT indicating the degree of overrepresentation in the dataset.
Figure 2Schematic diagrams illustrating the composition of multimeric RING E3 Ubiquitin ligases.
(A) SCF complex containing CUL1, (B) BTB complex containing CUL3.
Figure 3dnj-14 (tm3223) worms are delayed in ubiquitylated protein degradation
(A) Representative image of Western blot detection of GFP-UbV accumulation in PP563 and PP545 strains after overnight incubation with or without 10 μM bortezomib. There was no GFP detected in untreated PP563 worms but a signal was detectable after bortezomib treatment. In contrast GFP was already accumulated in PP545 worms before treatment. Quantitation using ImageJ showed that the average GFP signal from PP545 worm lysates after bortezomib treatment was 94% +/− 0.005% (+/−SEM) compared to untreated PP545 worms (n = 3). (B) Representative image of Western blot detection of GFP-UbV accumulation in N2 and dnj-14 (tm3223) crossed with the pSur5::UbV-GFP expressing strain, PP563, generating the strains, dnj-14 (wt); PP563 and dnj-14 (tm3223); PP563. There was an average intensity increase of 354 +/−109% (+/−SEM) in dnj-14 (tm3223); PP563 compared to dnj-14 (wt); PP563 (n = 3). Worms were harvested and lysed at day 1 of adulthood. 50 worms were lysed in each SDS-PAGE sample and anti-beta-actin was used as a loading control. (B) GFP fluorescence was imaged in dnj-14 (wt); PP563 and dnj-14 (tm3223); PP563 worms after overnight incubation with increasing concentrations of bortezomib. (C) Western blot detection of GFP-UbV accumulation, using an anti-GFP antibody, after overnight treatment of dnj-14 (wt); PP563 and dnj-14 (tm3223); PP563 with increasing concentrations of bortezomib. (D) Quantitation of anti-GFP signal detected in (C). Band intensity for 0 mM was assumed to be background and was subtracted from the band intensity for drug treated samples for the corresponding strain. All data was then normalised against the signal for dnj-14 (wt); PP563 at 0.5 mM. Error bars represent the standard error of the mean. Use of ANOVAR showed that data from the dnj-14 (tm3223) worms was statistically significantly different from the control worm data (n = 3, p < 0.02).